3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Vomiting
13
Nausea
6
Neoplasms
5
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Melanoma
1
Gynecologic Cancer
1
Genital Neoplasms, Female
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
74
Sunitinib
73
pembrolizumab
49
Everolimus
39
Sorafenib
36
Bevacizumab
36
Axitinib
36
cabozantinib
35
Radiosurgery
33
Ipilimumab
33
pazopanib
32
Magnetic Resonance Spectroscopy
27
Interleukin-2
27
aldesleukin
23
Specimen Handling
22
Cyclophosphamide
21
lenvatinib
20
fludarabine phosphate
17
Radiotherapy
16
Interferon-alpha
15
Peripheral Blood Stem Cell Transplantation
14
Gemcitabine
14
Biopsy
14
temsirolimus
13
Nephrectomy
13
durvalumab
11
Immunohistochemistry
11
CTLA-4 Antigen
11
Blood Specimen Collection
11
Capecitabine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Renal Cell
×
fosaprepitant
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts